体内研究 (In Vivo) |
RTI-371 (30 mg/kg;腹腔注射;单次给药) 在大鼠中可穿过血脑屏障,并在尾状核中置换体内 [125I]RTI-55 的结合,证实其可进入中枢神经系统并作用于 DAT 相关位点。
RTI-371 (1.0-170 mg/kg;腹腔注射;单次给药) 在 CD-1 小鼠及 Swiss-Webster 小鼠中仅产生轻微至弱的运动刺激效应,并表现为延迟性、低幅度的水平运动增加。
RTI-371 (3.0-100 mg/kg;腹腔注射;单次给药) 在 Swiss-Webster 小鼠中部分替代神经活性物质的辨别刺激作用,最大可达约 60-68% 的药物杠杆反应,并呈剂量依赖性降低反应速率。
RTI-371 (0.01-1.0 mg/kg/注射;静脉注射;自我给药程序) 在雄性 Sprague-Dawley 大鼠中不维持自我给药行为,其反应水平接近生理盐水,提示缺乏强化作用。
RTI-371 (1.0-17 mg/kg;腹腔注射;单次给药) 在雄性 Sprague-Dawley 大鼠中剂量依赖性抑制神经活性物质自我给药,并产生不可克服的拮抗作用,使剂量反应曲线整体下移。
RTI-371 (3.0-56 mg/kg;腹腔注射;[125I]RTI-121 静脉注射示踪;单次给药) 在 Swiss-Webster 小鼠中产生剂量与时间依赖性的 DAT 占据效应,在纹状体达到最大结合位点占据,并表现出较慢脑进入速率。
RTI-371 (3.0-30 mg/kg;腹腔注射;单次给药) 在野生型及 CB1 受体敲除小鼠中均可增加运动活动,且无基因型差异。
| Animal Model: |
Locomotor activity screening model (male CD-1 mice) |
| Dosage: |
Up to 30 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Displayed little or no effect on mouse horizontal locomotor activity, showing a poor correlation between locomotor stimulation and DAT inhibition.
Normalized locomotor stimulation score was reported as 5% (± 2%) of the maximum stimulation observed with 30 mg/kg cocaine. |
| Animal Model: |
In vivo [125I]RTI-55 displacement binding model (rats) |
| Dosage: |
Up to 30 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Crossed the blood-brain barrier and successfully entered the central nervous system, as evidenced by its ability to displace the in vivo binding of the radioligand [125I]RTI-55 in the rat caudate. |
| Animal Model: |
Swiss-Webster mice locomotor activity model |
| Dosage: |
1.0, 3.0, 10, 20, 30, 40, 56, 100, and 170 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Exhibited less effectiveness in stimulating locomotion, and was ineffective in the first 30 minutes after injection.
Increased horizontal ambulatory activity at later times over the course of the observation period to a maximum mean of 266 counts/min at the 100 mg/kg dose from 60 to 90 minutes after injection. |
| Animal Model: |
Cocaine/saline drug-discrimination procedure in Swiss-Webster mice |
| Dosage: |
3.0, 10, 17, 30, and 56 mg/kg (for 5-min pre-session treatment); 10, 30, 56, and 100 mg/kg (for 60-min pre-session treatment) |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Incompletely substituted for cocaine, reaching a maximum of approximately 60% to 68% drug-lever responding at 5 minutes or 1 hour after injection.
Produced a level of substitution greater than that produced by saline, although some subjects showed full substitution at some doses while others showed less than 33% drug-appropriate responding.
Produced dose-related decreases in rates of responding, with decreases at 5 minutes occurring at lower doses than at 60 minutes after injection. |
| Animal Model: |
Cocaine self-administration and substitution model in male Sprague-Dawley rats |
| Dosage: |
0.01, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection (unit doses under a five-component procedure) |
| Administration: |
Intravenous injection (i.v.), single dose |
| Result: |
Maintained low response rates throughout the experimental session that were not different from those obtained when saline injections were available.
Maintained response rates well below those maintained by cocaine, and showed no significant differences between any dose per injection compared with the extinction component.
Demonstrated that the compound itself was not self-administered. |
| Animal Model: |
Presession treatment on cocaine self-administration in male Sprague-Dawley rats |
| Dosage: |
1.0, 3.2, 10, and 17 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Dose-dependently decreased maximal cocaine self-administration more potently than food-maintained responding, with ED50 values of 3.33 mg/kg for cocaine-maintained responding and 8.21 mg/kg for food presentation.
Produced an insurmountable antagonism of cocaine self-administration, shifting the cocaine self-administration dose-effect curve downward rather than leftward.
Increased the pauses before initiation of responding and caused responding to cease before the end of the components at the 10 mg/kg dose, where no dose of cocaine maintained responding above saline levels. |
| Animal Model: |
In vivo [125I]RTI-121 binding and DAT occupancy model in Swiss-Webster mice |
| Dosage: |
3.0, 10, 30, and 56 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.) for compound; intravenous injection (i.v.) via tail vein for [125I]RTI-121; single dose |
| Result: |
Produced a dose- and time-related displacement of [125I]RTI-121 binding in the striatum, reaching maximum displacement with 56 mg/kg at 60 min.
Exhibited the least steep slopes fitted to the time course of displacement among tested drugs, with a displacement rate of 0.320%/min at 56 mg/kg.
Demonstrated the slowest apparent association rate and in vivo DAT occupancy among tested drugs, approximately one-half of RTI-336 and one-fourth of cocaine. |
| Animal Model: |
Locomotor activity model in cannabinoid CB1 receptor wild-type and knockout mice |
| Dosage: |
3.0, 10, and 30 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), single dose |
| Result: |
Increased horizontal ambulatory activity from 60 to 90 min after injection, with maximum mean ambulatory counts of 100 and 74.4 counts/min at 30 mg/kg for wild-type and knockout mice, respectively.
Stimulated activity from 120 to 150 min after injection but was less effective.
Showed no significant effect of genotype or dose-dependent differences, indicating that cannabinoid CB1 receptors do not decrease its cocaine-like stimulation or mediate its unique effects. |
|